We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 2,583

OIG Advisory Opinion Permits Refunding Device Purchase Price Under Limited Conditions
  • Cooley LLP
  • USA
  • September 21 2018

On September 17, 2018, the Office of Inspector General (“OIG”) issued Advisory Opinion No. 18-10 regarding a proposed arrangement in which a surgical


Clinical trials in Switzerland
  • Bär & Karrer
  • Switzerland, Global
  • September 3 2018

A structured guide to clinical trials in Switzerland


CMS Allows Medicare Part D Indication-Based Formulary Design
  • Holland & Knight LLP
  • USA
  • August 30 2018

The Centers for Medicare and Medicaid Services (CMS) has just announced a significant shift in Medicare Part D formulary design to allow Part D


Reliance on Inherently Disclosed Embodiments in Prior Art is Dangerous
  • Haynes and Boone LLP
  • USA
  • August 28 2018

Prior art disclosures, and particularly non-patent literature, can be relied on for more than what they explicitly disclose. For example, many prior


Medicare and Medicaid Providers: Choose Your Vendors WiselyBut Be Sure to Pay Them at Fair Market Value and for Bona Fide Services
  • Cadwalader Wickersham & Taft LLP
  • USA
  • August 27 2018

Health care providers will often try to negotiate and receive fair, commercially reasonable business terms with vendors and suppliers, to both better


Hospice Providers Take Note: OIG Highlights Compliance Vulnerabilities in the Medicare Hospice Benefit
  • Dykema Gossett PLLC
  • USA
  • August 20 2018

For a number of years, the Office of the Inspector General (OIG) of the U.S. Department of Health and Human Services has published concerns about the


Hospital Compliance Officer’s Opposition to Termination of Co-Worker States a Claim of FMLA Retaliation
  • Jackson Lewis PC
  • USA
  • August 9 2018

The United States District Court for the District of Columbia recently denied a Hospital’s motion to dismiss a Family and Medical Leave Act (“FMLA”)


CMS Releases Guidance Allowing Step Therapy for Part B Drugs
  • Cooley LLP
  • USA
  • August 7 2018

Today, the Centers for Medicare & Medicaid Services (CMS) released guidance and a Fact Sheet that will provide Medicare Advantage (MA) plans the


PTAB Institutes a Second IPR on Rituxan-related ’821 Patent
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • August 1 2018

The PTAB recently instituted a second IPR of US Patent 9,296,821 (“the ’821 patent”), which covers certain uses of Rituxan (rituximab), a monoclonal


Employment Law Commentary - Volume 30, Issue 7 - July 2018
  • Morrison & Foerster LLP
  • USA
  • July 23 2018

Overview of Family Responsibilities Discrimination. Family Responsibilities Discrimination (FRD) is an umbrella term for employment discrimination